Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2009-015984-15 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sanfilippo syndrome, or Mucopolysaccharidosis (MPS) III, is a rare lysosomal storage disease (LSD) caused by loss in activity of 1 of 4 enzymes necessary for degradation of the glycosaminoglycan (GAG) heparan sulfate (HS) in lysosomes. MPS IIIA results from deficiency of the enzyme heparan N-sulfatase (sulfamidase). MPS IIIA symptoms arise on average at 7 months of age, with the average age of diagnosis at 4.5 years for the majority of patients. The central nervous system (CNS) is the most severely affected organ system in patients with MPS IIIA, evidenced by deficits in language development, motor skills, and intellectual development. In addition, there are abnormal behaviors including but not limited to aggression and excess motor activity/hyperactivity that contribute to disturbances in sleep.Overall, individuals with MPS IIIA have a marked developmental delay and significantly reduced lifespan of 15 years of age on average.
The purpose of this study is to determine the safety and tolerability of rhHNS via ascending doses administered via an a surgically implanted intrathecal drug delivery device (IDDD) intrathecal (IT) route once monthly (or every two weeks) for 6 months in patients with MPS IIIA.
No effective, disease-modifying therapies are currently approved as treatments for this devastating and disabling disease.
Shire Human Genetic Therapies (Shire HGT) is developing a sulfamidase enzyme replacement therapy (ERT)rhHNS for patients with MPS IIIA. recombinant human heparan-N-sulfatase (rhHNS) is being administered into the cerebrospinal fluid (CSF) via an surgically implanted intrathecal drug delivery device (IDDD), because when administered intravenously (IV) it does not cross the blood brain barrier (BBB).
This study is a multicenter, multiple-dose, dose escalation study designed to evaluate the safety, tolerability, and clinical activity of up to 3 dose levels (10mg,45mg and 90mg monthly for 6 months) of rhHNS administered via an IDDD in patients with Sanfilippo syndrome Type A ages greater than or equal to 3 years of age.
Patients who have completed all study requirements in this study will be invited to participate in an open-label extension study that will be designed to evaluate long term safety and clinical outcomes of intrathecal administration of rhHNS.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 10 mg rhHNS | Experimental | 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months |
|
| 45 mg rhHNS | Experimental | 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months |
|
| 90 mg rhHNS | Experimental | Given IDDD as a 45 mg dose every 14 [±2 days] for a monthly total of 90 mg for 6 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Recombinant human heparan N-sulfatase (rhHNS) | Biological |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Treatment Emergent Serious Adverse Events (SAE) | An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures. | Baseline to week 30 (follow-up) |
| Number of Treatment Emergent Adverse Events (TEAE) | An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures. | Baseline to week 30 (follow-up) |
| Summary of Anti-rhHNS Antibody Status in Cerebrospinal Fluid (CSF) by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group | Participants with positive, negative and missing status were reported. | Baseline, Week 26 |
| Summary of Anti-rhHNS Antibody Status in Serum by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group | Participants with positive, negative and missing status were reported. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Developmental Quotient (DQ) Using Bayley Scales of Infant Development Third Edition (BSID III) and Kaufman Assessment Battery for Children Second Edition (KABC II) at Week 22 | BSID-III was used to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers. This measure consists of a series of developmental play tasks. Raw scores of successfully completed items are converted to scale scores and to composite scores. The mean composite score is 100 and the standard deviation (SD) is 15.Higher scores are indicative of decreased development. KABC-II was an individually administered measure of the processing and reasoning abilities of children and adolescents between the ages of 3 and 18 years and is an alternative to BSID-III. BSID-III DQ score was based on the Cognitive domain. The DQ score was calculated from the data obtained from either BSID-III/KABC-II mental age equivalent of the child in months divided by the calendar age in months (multiplied by 100 to give percentage points). |
Not provided
Inclusion Criteria
Each patient had to meet the following criteria to be eligible for the study:
a.) Patients had a documented deficiency in sulfamidase enzyme activity of ≤10% of the lower limit of the normal range as measured in fibroblasts or leukocytes.
AND either b or c b.) Patients had a normal enzyme activity level of at least 1 other sulfatase (to rule out multiple sulfatase deficiency) as measured in fibroblasts or leukocytes.
c.) Patients had 2 documented mutations.
The patient was ≥3 years of age and had a developmental age ≥1 year.
Patients must have been medically stable, in the opinion of the Investigator, to accommodate the protocol requirements, including travel, assessments, and IDDD surgery, without placing an undue burden on the patient/patient's family.
The patient's parent(s) or legal guardian must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient, the patient's parent(s), or legal guardian. The patients, patient's parents or legal guardian's consent and patient's assent as appropriate, must have been obtained.
Exclusion Criteria
Patients who met any of the following criteria were excluded from the study:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Study Director | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emma Children's Hospital, Academic Medical Center | Amsterdam | 1105 AZ | Netherlands | |||
| St. Mary's Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27211612 | Derived | Jones SA, Breen C, Heap F, Rust S, de Ruijter J, Tump E, Marchal JP, Pan L, Qiu Y, Chung JK, Nair N, Haslett PAJ, Barbier AJ, Wijburg FA. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab. 2016 Jul;118(3):198-205. doi: 10.1016/j.ymgme.2016.05.006. Epub 2016 May 10. | |
| 25421091 |
Not provided
Not provided
Study enrolled 12 participants and 4 participants were included in each of the 3 dose groups.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | HGT-1410 10 mg | HGT-1410/rhHNS 10 milligram (mg) monthly via an intrathecal drug delivery device (IDDD) (every 28 [±7 days]) for a total of 6 months. |
| FG001 | HGT-1410 45 mg | HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months. |
| FG002 | HGT-1410 90 mg | HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | HGT-1410 10 mg | HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months. |
| BG001 | HGT-1410 45 mg | HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Treatment Emergent Serious Adverse Events (SAE) | An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures. | Safety population was defined as all enrolled participants who received at least 1 dose (full or partial) of study drug. | Posted | Number | events | Baseline to week 30 (follow-up) |
|
Baseline to Week 30 (follow-up)
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | HGT-1410 10 mg | HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Device breakage | General disorders | MedDRA 12.1 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Tympanic membrane disorder | Ear and labyrinth disorders | MedDRA 12.1 | Systematic Assessment |
Comparison to values obtained in a longitudinal, 12 month, natural history study of untreated participants with MPS IIIA was not reported as it was to be compared with another study protocol HGT-SAN-053 (NCT01047306).
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Shire | +1 866 842 5335 | ClinicalTransparency@shire.com |
Not provided
| ID | Term |
|---|---|
| D009083 | Mucopolysaccharidoses |
| D009084 | Mucopolysaccharidosis III |
| D016464 | Lysosomal Storage Diseases |
| ID | Term |
|---|---|
| D002239 | Carbohydrate Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline, Week 26 |
| Number of Participants With Intrathecal Drug Device (IDDD) Failures at Week 26 | Participants with IDDD failures were reported. | Week 26 |
| Baseline, Week 22 |
| Change From Baseline in Four Point Scoring System/Total Disability Score (FPSS/TDS) at Week 22 and Week 26 (EOS) | FPSS is a sanfilippo-specific disability assessment which assesses motor function, expressive/speech language, and cognitive function on a 0 to 3 point scale. A score of 3 points is assigned for normal function, 2 points for beginning of regression, 1 point for severe level of regression, and 0 points for lost skills. The total disability score (TDS) is the average (0-3) of the motor skills (MS), speech abilities (SA), and cognitive function (CF) scores. Lower scores indicate developmental regression. | Baseline, Week 22, Week 26 |
| Change From Baseline in Sanfilippo Behavioral Rating Scale (SBRS) at Week 22 and Week 26 (EOS) | SBRS a parent-scored behavioral inventory measuring: comprehensive language skills, expressive language skills, tantrums, mood and emotions, and other behaviors not otherwise classified. Subscale items are scored 0=Never, 1=Occasionally(5-10%), 2=Sometimes (25%), 3=About half the time, 4=Often(75%), 5=Almost always (90%), 6=Always. Summary scores are the sum of responses within a given domain. Higher values = undesirable behavior. Total score range listed below with the abbreviations. Current Communication (CC)(0-42), Past Communication (PC)(0-42), Orality (0-36), Body Movements (BM)(0-30), Interaction With Objects (IWO)(0-24), Activity And Routines (AAR)(0-36), Emotional Function (EF)(0-18), Safety-consciousness (SC)(0-18), Fearfulness (0-36), Social Interaction (SI)(0-36), Eye Contact (EC)(0-18), Emotional Engagement (EE)(0-18), Comfort Seeking (CS)(0-30), Attention (0-18), Self-control/Compliance (SCC)(0-18), Mood, Anger/Aggression (MAA)(0-42), Self-gratification (SG)(0-24). | Baseline, Week 22, Week 26/EOS |
| Change From Baseline in Developmental Quotient (DQ) Using Vineland Adaptive Behavioral Scales Second Edition (VABS-II) at Week 22 | VABS-II measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. It is an instrument that supports the diagnosis of intellectual and developmental disabilities in participants. This test measures 5 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behavior composite (a composite of the other four domains). Scoring is 'Usually' = 2, 'Sometimes'/Partially' = 1 or 'Never' = 0. The raw scores will be converted to domain standard scores (mean 100, SD 15). Higher scores indicate undesirable behavior. The Overall DQ score was calculated from the mean age-equivalent score obtained by averaging out the age equivalent scores for all the sub-domains except for Gross and Fine motor skills. | Baseline, Week 22 |
| Change From Baseline in Movement Assessment Battery for Children Second Edition (MABC-2) at Week 26 (EOS) | Movement Assessment Battery for Children, Second Edition (MABC-II) was to be used to identify, describe and guide the treatment of motor impairment in children from 3.0 to 16:11 years of age. As per statistical analysis plan, the outcome was to be assessed only if greater than (>) 50 percent (%) of participants were available for the evaluation. | Baseline, Week 26/EOS |
| Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Parent Form 50 (CHQ-PF50) Questions at Week 22 and Week 26 (EOS) | CHQ-PF50 which was designed to measure the physical and psychosocial well-being of children 5 years to 18 years of age, consists of 13 health concepts including 11 multi-item and 2 single item scales: Physical Function (PF), Role/Social-Emotional/Behavioral (REB), Role/Social-Physical (RP), bodily pain (BP), General Behavior (BE), Mental Health (MH), Self Esteem (SE), General Health Perceptions (GH), Change in Health (CH), Parental Impact-Emotional (PE), Parental Impact-Time (PT), Family Activities (FA), and Family Cohesion (FC). Transformed scores for all subscales range from 0 to 100, with a higher score indicating better health. Physical and Psychosocial Summary measures (SM) were scored with the use of norm-based methods that standardize the scores to a mean (± Standard Deviation) of 50 ± 10 on the basis of an assessment of the general United States population. Higher values represent better health. | Baseline, Week 22, Week 26/EOS |
| Change From Baseline in Quality of Life (QoL) Using Infant Toddler Quality of Life Questionnaire™ (ITQOL) at Week 22 and Week 26 (EOS) | ITQOL is a generic, validated health status measure for children aged 2 months up to 5 years, including items and scales to measure aspects of physical functioning, development, pain, mood, behavior, general health and impact on parents. The ITQOL consists of 97 items that are scored, summed, and transformed on a scale from 0 (worst health) to 100 (best health). The score range for all individual subscales is 0 (worst health) to 100 (best health). Abbreviation: Overall Health (OH), Physical Abilities (PA), Growth And Development (GAD), Bodily Pain (BP), Temperament And Moods (TAM), General Behavior (GEB), Global Behavior (GLB), Getting Along (GA), General Health Perceptions (GHP), PI-Emotion (PIE), PI-Time (PIT), Family Cohesion (FC). | Baseline, Week 22, Week 26/EOS |
| Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Child Form 87 (CHQ-CF87) at Week 26 (EOS) | CHQ-CF87 form was designed to be a self-report for participants 10 years and older. It consists of 87 questions and contains the same scales as the PF-50, (with the omission of the parental impact scales and there are no psychosocial and physical summary scores derived). As per statistical analysis plan, the outcome was to be assessed only if greater than (>) 50 percent (%) of participants were available for the evaluation. | Baseline, Week 26/EOS |
| Change From Baseline in Quality of Life (QoL) Using Children's Sleep Habits Rating Scale at Week 22 and Week 26 (EOS) | Children's sleep habits rating scale consisting of 35 item parent questionnaire sleep screening tool. Items are scored on a 3-point scale from 1 (rarely) to 3 (usually) with a Total Sleep Disturbance score (TSDS) ranging from 35-105. Eight subscale scores are totaled to create the TSDS. The subscales are: Bedtime Resistance (BR)(6 items, score = 6-18), Sleep Duration (SD)(3 items, score = 3-9), Parasomnias (P)(7 items, score = 7-21), Sleep Disordered Breathing (SDB)(3 items, score = 3-9), Night Waking (NW)(3 items, score = 3-9), Daytime Sleepiness (DS)(8 items, score = 8-24), Sleep Anxiety (SA)(4 items, score = 4-12), and Sleep Onset Delay (SOD)(1 item, score = 1-3). The questionnaire was designed for children aged 4 through 12 years. A higher score is indicative of more disturbed sleep. | Baseline, Week 22, Week 26/EOS |
| Number of Participants With Accumulation of Recombinant Human Heparan N-Sulfatase (rhHNS) in Cerebrospinal Fluid (CSF) at Week 22 | Cerebrospinal fluid samples were collected from participants through an implanted IDDD or via lumbar puncture (LP) immediately prior to each administration of HGT-1410. | Baseline, Week 22 |
| Change From Baseline in Concentration of Heparan Sulfate and Heparan Sulfate Derivatives in Cerebrospinal Fluid (CSF) at Week 6, 10, 14, 18, 22 and 26(EOS) | Levels of heparan sulfate and its derivatives were evaluated using the proprietary Sensi-Pro (SP) high-performance liquid chromatography (HPLC) based assay. Abbreviation: SP Total Heparan Sulfate (SPTHS), SP Non-Reducing End Assay (SPNREA), | Baseline, Week 6, 10, 14, 18, 22 and 26(EOS) |
| Change From Baseline in Brain Magnetic Resonance Imaging (MRI) at Week 22 | Brain MRI was measured for grey matter volume (GMV) , white matter volume (WMV) and Intracranial cerebrospinal fluid Volume (ICSFV) (Ventricles + Additional CSF Space). | Baseline, Week 22 |
| Change From Baseline in Mean Auditory Brainstem Response (ABR) at Week 22 | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Mean ABR air and bone conduction threshold were assessed. Mean ABR bone conduction threshold was not possible to be reported as there was insufficient data to be analysed. | Baseline, Week 22 |
| Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Latencies | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. The Inter-peak Latencies (IPL) were calculated by subtracting the absolute latencies (AL). The Inter-aural Latencies (IAL) were calculated by subtracting the absolute wave V latencies of the right and left ear. IAL, IPL and AL were reported. Abbreviation: Right Ear (RE), Left Ear (LE), Wave (W), Wave V (WV) | Baseline, Week 22 |
| Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitudes | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes by left ear (LE) and right ear (RE) were reported. | Baseline, Week 22 |
| Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitude Ratio | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes(A), log-transformed amplitudes (LTA), square-root transformed amplitudes (STA) by left ear (LE) and right ear (RE) wave V/I in ratio was reported. | Baseline, Week 22 |
| Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Latencies | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed latencies (LTL) by left and right ear were reported. | Baseline, Week 22 |
| Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Amplitude | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed amplitudes (LTA) by left and right ear were reported. | Baseline, Week 22 |
| Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Latencies | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed latency (STL) by left and right ear were reported. | Baseline, Week 22 |
| Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Amplitude | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed amplitude (STA) by left and right ear were reported. | Baseline, Week 22 |
| Manchester |
| M13 9WL |
| United Kingdom |
| King B, Marshall N, Beard H, Hassiotis S, Trim PJ, Snel MF, Rozaklis T, Jolly RD, Hopwood JJ, Hemsley KM. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain. J Inherit Metab Dis. 2015 Mar;38(2):341-50. doi: 10.1007/s10545-014-9790-8. Epub 2014 Nov 25. |
| 22547151 | Derived | Langford-Smith A, Wilkinson FL, Langford-Smith KJ, Holley RJ, Sergijenko A, Howe SJ, Bennett WR, Jones SA, Wraith J, Merry CL, Wynn RF, Bigger BW. Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol Ther. 2012 Aug;20(8):1610-21. doi: 10.1038/mt.2012.82. Epub 2012 May 1. |
| BG002 | HGT-1410 90 mg | HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months. |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months. |
| OG001 | HGT-1410 45 mg | HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months. |
| OG002 | HGT-1410 90 mg | HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months. |
|
|
| Primary | Number of Treatment Emergent Adverse Events (TEAE) | An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures. | Safety population. | Posted | Number | events | Baseline to week 30 (follow-up) |
|
|
|
| Primary | Summary of Anti-rhHNS Antibody Status in Cerebrospinal Fluid (CSF) by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group | Participants with positive, negative and missing status were reported. | Intent to treat (ITT) population was defined as all enrolled participants who received at least 1 dose (full or partial) of study drug. | Posted | Number | participants | Baseline, Week 26 |
|
|
|
| Primary | Summary of Anti-rhHNS Antibody Status in Serum by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group | Participants with positive, negative and missing status were reported. | ITT population | Posted | Number | participants | Baseline, Week 26 |
|
|
|
| Primary | Number of Participants With Intrathecal Drug Device (IDDD) Failures at Week 26 | Participants with IDDD failures were reported. | ITT population. | Posted | Number | participants | Week 26 |
|
|
|
| Secondary | Change From Baseline in Developmental Quotient (DQ) Using Bayley Scales of Infant Development Third Edition (BSID III) and Kaufman Assessment Battery for Children Second Edition (KABC II) at Week 22 | BSID-III was used to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers. This measure consists of a series of developmental play tasks. Raw scores of successfully completed items are converted to scale scores and to composite scores. The mean composite score is 100 and the standard deviation (SD) is 15.Higher scores are indicative of decreased development. KABC-II was an individually administered measure of the processing and reasoning abilities of children and adolescents between the ages of 3 and 18 years and is an alternative to BSID-III. BSID-III DQ score was based on the Cognitive domain. The DQ score was calculated from the data obtained from either BSID-III/KABC-II mental age equivalent of the child in months divided by the calendar age in months (multiplied by 100 to give percentage points). | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Four Point Scoring System/Total Disability Score (FPSS/TDS) at Week 22 and Week 26 (EOS) | FPSS is a sanfilippo-specific disability assessment which assesses motor function, expressive/speech language, and cognitive function on a 0 to 3 point scale. A score of 3 points is assigned for normal function, 2 points for beginning of regression, 1 point for severe level of regression, and 0 points for lost skills. The total disability score (TDS) is the average (0-3) of the motor skills (MS), speech abilities (SA), and cognitive function (CF) scores. Lower scores indicate developmental regression. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Week 22, Week 26 |
|
|
|
| Secondary | Change From Baseline in Sanfilippo Behavioral Rating Scale (SBRS) at Week 22 and Week 26 (EOS) | SBRS a parent-scored behavioral inventory measuring: comprehensive language skills, expressive language skills, tantrums, mood and emotions, and other behaviors not otherwise classified. Subscale items are scored 0=Never, 1=Occasionally(5-10%), 2=Sometimes (25%), 3=About half the time, 4=Often(75%), 5=Almost always (90%), 6=Always. Summary scores are the sum of responses within a given domain. Higher values = undesirable behavior. Total score range listed below with the abbreviations. Current Communication (CC)(0-42), Past Communication (PC)(0-42), Orality (0-36), Body Movements (BM)(0-30), Interaction With Objects (IWO)(0-24), Activity And Routines (AAR)(0-36), Emotional Function (EF)(0-18), Safety-consciousness (SC)(0-18), Fearfulness (0-36), Social Interaction (SI)(0-36), Eye Contact (EC)(0-18), Emotional Engagement (EE)(0-18), Comfort Seeking (CS)(0-30), Attention (0-18), Self-control/Compliance (SCC)(0-18), Mood, Anger/Aggression (MAA)(0-42), Self-gratification (SG)(0-24). | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Week 22, Week 26/EOS |
|
|
|
| Secondary | Change From Baseline in Developmental Quotient (DQ) Using Vineland Adaptive Behavioral Scales Second Edition (VABS-II) at Week 22 | VABS-II measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. It is an instrument that supports the diagnosis of intellectual and developmental disabilities in participants. This test measures 5 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behavior composite (a composite of the other four domains). Scoring is 'Usually' = 2, 'Sometimes'/Partially' = 1 or 'Never' = 0. The raw scores will be converted to domain standard scores (mean 100, SD 15). Higher scores indicate undesirable behavior. The Overall DQ score was calculated from the mean age-equivalent score obtained by averaging out the age equivalent scores for all the sub-domains except for Gross and Fine motor skills. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Movement Assessment Battery for Children Second Edition (MABC-2) at Week 26 (EOS) | Movement Assessment Battery for Children, Second Edition (MABC-II) was to be used to identify, describe and guide the treatment of motor impairment in children from 3.0 to 16:11 years of age. As per statistical analysis plan, the outcome was to be assessed only if greater than (>) 50 percent (%) of participants were available for the evaluation. | This outcome measure was not analyzed as it does not meet the pre-specified SAP criteria (outcome was to be assessed only if greater than (>) 50 percent (%) of participants were available for the evaluation). | Posted | Baseline, Week 26/EOS |
|
|
| Secondary | Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Parent Form 50 (CHQ-PF50) Questions at Week 22 and Week 26 (EOS) | CHQ-PF50 which was designed to measure the physical and psychosocial well-being of children 5 years to 18 years of age, consists of 13 health concepts including 11 multi-item and 2 single item scales: Physical Function (PF), Role/Social-Emotional/Behavioral (REB), Role/Social-Physical (RP), bodily pain (BP), General Behavior (BE), Mental Health (MH), Self Esteem (SE), General Health Perceptions (GH), Change in Health (CH), Parental Impact-Emotional (PE), Parental Impact-Time (PT), Family Activities (FA), and Family Cohesion (FC). Transformed scores for all subscales range from 0 to 100, with a higher score indicating better health. Physical and Psychosocial Summary measures (SM) were scored with the use of norm-based methods that standardize the scores to a mean (± Standard Deviation) of 50 ± 10 on the basis of an assessment of the general United States population. Higher values represent better health. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Week 22, Week 26/EOS |
|
|
|
| Secondary | Change From Baseline in Quality of Life (QoL) Using Infant Toddler Quality of Life Questionnaire™ (ITQOL) at Week 22 and Week 26 (EOS) | ITQOL is a generic, validated health status measure for children aged 2 months up to 5 years, including items and scales to measure aspects of physical functioning, development, pain, mood, behavior, general health and impact on parents. The ITQOL consists of 97 items that are scored, summed, and transformed on a scale from 0 (worst health) to 100 (best health). The score range for all individual subscales is 0 (worst health) to 100 (best health). Abbreviation: Overall Health (OH), Physical Abilities (PA), Growth And Development (GAD), Bodily Pain (BP), Temperament And Moods (TAM), General Behavior (GEB), Global Behavior (GLB), Getting Along (GA), General Health Perceptions (GHP), PI-Emotion (PIE), PI-Time (PIT), Family Cohesion (FC). | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Week 22, Week 26/EOS |
|
|
|
| Secondary | Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Child Form 87 (CHQ-CF87) at Week 26 (EOS) | CHQ-CF87 form was designed to be a self-report for participants 10 years and older. It consists of 87 questions and contains the same scales as the PF-50, (with the omission of the parental impact scales and there are no psychosocial and physical summary scores derived). As per statistical analysis plan, the outcome was to be assessed only if greater than (>) 50 percent (%) of participants were available for the evaluation. | This outcome measure was not analyzed as it does not meet the pre-specified SAP criteria (outcome was to be assessed only if greater than (>) 50 percent (%) of participants were available for the evaluation). | Posted | Baseline, Week 26/EOS |
|
|
| Secondary | Change From Baseline in Quality of Life (QoL) Using Children's Sleep Habits Rating Scale at Week 22 and Week 26 (EOS) | Children's sleep habits rating scale consisting of 35 item parent questionnaire sleep screening tool. Items are scored on a 3-point scale from 1 (rarely) to 3 (usually) with a Total Sleep Disturbance score (TSDS) ranging from 35-105. Eight subscale scores are totaled to create the TSDS. The subscales are: Bedtime Resistance (BR)(6 items, score = 6-18), Sleep Duration (SD)(3 items, score = 3-9), Parasomnias (P)(7 items, score = 7-21), Sleep Disordered Breathing (SDB)(3 items, score = 3-9), Night Waking (NW)(3 items, score = 3-9), Daytime Sleepiness (DS)(8 items, score = 8-24), Sleep Anxiety (SA)(4 items, score = 4-12), and Sleep Onset Delay (SOD)(1 item, score = 1-3). The questionnaire was designed for children aged 4 through 12 years. A higher score is indicative of more disturbed sleep. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Week 22, Week 26/EOS |
|
|
|
| Secondary | Number of Participants With Accumulation of Recombinant Human Heparan N-Sulfatase (rhHNS) in Cerebrospinal Fluid (CSF) at Week 22 | Cerebrospinal fluid samples were collected from participants through an implanted IDDD or via lumbar puncture (LP) immediately prior to each administration of HGT-1410. | ITT population. | Posted | Number | participants | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Concentration of Heparan Sulfate and Heparan Sulfate Derivatives in Cerebrospinal Fluid (CSF) at Week 6, 10, 14, 18, 22 and 26(EOS) | Levels of heparan sulfate and its derivatives were evaluated using the proprietary Sensi-Pro (SP) high-performance liquid chromatography (HPLC) based assay. Abbreviation: SP Total Heparan Sulfate (SPTHS), SP Non-Reducing End Assay (SPNREA), | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | picomole per milliliter (pmol/mL) | Baseline, Week 6, 10, 14, 18, 22 and 26(EOS) |
|
|
|
| Secondary | Change From Baseline in Brain Magnetic Resonance Imaging (MRI) at Week 22 | Brain MRI was measured for grey matter volume (GMV) , white matter volume (WMV) and Intracranial cerebrospinal fluid Volume (ICSFV) (Ventricles + Additional CSF Space). | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | milliliter (mL) | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Mean Auditory Brainstem Response (ABR) at Week 22 | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Mean ABR air and bone conduction threshold were assessed. Mean ABR bone conduction threshold was not possible to be reported as there was insufficient data to be analysed. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | Decibel Above Normal Adult Hearing Level | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Latencies | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. The Inter-peak Latencies (IPL) were calculated by subtracting the absolute latencies (AL). The Inter-aural Latencies (IAL) were calculated by subtracting the absolute wave V latencies of the right and left ear. IAL, IPL and AL were reported. Abbreviation: Right Ear (RE), Left Ear (LE), Wave (W), Wave V (WV) | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | millisecond (ms) | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitudes | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes by left ear (LE) and right ear (RE) were reported. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | microvolt (mcV) | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitude Ratio | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes(A), log-transformed amplitudes (LTA), square-root transformed amplitudes (STA) by left ear (LE) and right ear (RE) wave V/I in ratio was reported. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | ratio | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Latencies | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed latencies (LTL) by left and right ear were reported. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | log transformed (latency [ms]) | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Amplitude | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed amplitudes (LTA) by left and right ear were reported. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | log transformed (amplitude [mcV]) | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Latencies | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed latency (STL) by left and right ear were reported. | ITT population.Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | square-root transformed (latency [ms]) | Baseline, Week 22 |
|
|
|
| Secondary | Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Amplitude | ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed amplitude (STA) by left and right ear were reported. | ITT population. Here, n = participants evaluable for specified category for each arm, respectively. | Posted | Mean | Standard Deviation | square-root transformed(amplitude [mcV]) | Baseline, Week 22 |
|
|
|
| 3 |
| 4 |
| 4 |
| 4 |
| EG001 | HGT-1410 45 mg | HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months. | 3 | 4 | 4 | 4 |
| EG002 | HGT-1410 90 mg | HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months. | 1 | 4 | 4 | 4 |
| Device component issue | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Device failure | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Postoperative wound infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Viral infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Medical device change | Surgical and medical procedures | MedDRA 12.1 | Systematic Assessment |
|
| Abnormal faeces | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment |
|
| Regurgitation | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment |
|
| Administration site pain | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Catheter site erythema | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Device breakage | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Device failure | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Implant site swelling | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Irritability | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Malaise | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Medical device complication | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Pain | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA 12.1 | Systematic Assessment |
|
| Seasonal allergy | Immune system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Candida nappy rash | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Otitis externa | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Otitis media | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Post procedural infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Postoperative wound infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Proteus infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Rhinitis | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Viral rash | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Viral upper respiratory tract infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA 12.1 | Systematic Assessment |
|
| Open wound | Injury, poisoning and procedural complications | MedDRA 12.1 | Systematic Assessment |
|
| Post procedural discomfort | Injury, poisoning and procedural complications | MedDRA 12.1 | Systematic Assessment |
|
| Procedural pain | Injury, poisoning and procedural complications | MedDRA 12.1 | Systematic Assessment |
|
| Procedural site reaction | Injury, poisoning and procedural complications | MedDRA 12.1 | Systematic Assessment |
|
| Procedural vomiting | Injury, poisoning and procedural complications | MedDRA 12.1 | Systematic Assessment |
|
| CSF protein increased | Investigations | MedDRA 12.1 | Systematic Assessment |
|
| CSF white blood cell count increased | Investigations | MedDRA 12.1 | Systematic Assessment |
|
| Haemoglobin decreased | Investigations | MedDRA 12.1 | Systematic Assessment |
|
| Lymphocyte count increased | Investigations | MedDRA 12.1 | Systematic Assessment |
|
| Neutrophil count decreased | Investigations | MedDRA 12.1 | Systematic Assessment |
|
| Norovirus test positive | Investigations | MedDRA 12.1 | Systematic Assessment |
|
| Serum ferritin decreased | Investigations | MedDRA 12.1 | Systematic Assessment |
|
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment |
|
| Trigger finger | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment |
|
| Cauda equina syndrome | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Cognitive disorder | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Crying | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Drooling | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Memory impairment | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Motor dysfunction | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Paraesthesia | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Psychomotor hyperactivity | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Syncope | Nervous system disorders | MedDRA 12.1 | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | MedDRA 12.1 | Systematic Assessment |
|
| Depressed mood | Psychiatric disorders | MedDRA 12.1 | Systematic Assessment |
|
| Restlessness | Psychiatric disorders | MedDRA 12.1 | Systematic Assessment |
|
| Micturition urgency | Renal and urinary disorders | MedDRA 12.1 | Systematic Assessment |
|
| Urinary incontinence | Renal and urinary disorders | MedDRA 12.1 | Systematic Assessment |
|
| Labia enlarged | Reproductive system and breast disorders | MedDRA 12.1 | Systematic Assessment |
|
| Penile adhesion | Reproductive system and breast disorders | MedDRA 12.1 | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment |
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment |
|
| Dermatitis | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment |
|
| Dermatitis allergic | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment |
|
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment |
|
| Infection prophylaxis | Surgical and medical procedures | MedDRA 12.1 | Systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA 12.1 | Systematic Assessment |
|
| Pallor | Vascular disorders | MedDRA 12.1 | Systematic Assessment |
|
Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.
| D017520 | Mucinoses |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| Title | Measurements |
|---|---|
|
| Missing (Baseline) |
|
| Negative (Week 26) |
|
| Positive (Week 26) |
|
| Missing (Week 26) |
|
| Title | Measurements |
|---|---|
|
| Missing (Baseline) |
|
| Negative (Week 26) |
|
| Positive (Week 26) |
|
| Missing (Week 26) |
|
|
|
| MS: Change at Week 26/EOS (n=2,2,3) |
|
| SA: Baseline (n= 4, 3, 4) |
|
| SA: Change at Week 22 (n= 4, 3, 4) |
|
| SA: Change at Week 26/EOS (n= 2, 2, 3) |
|
| CF: Baseline (n= 4, 3, 4) |
|
| CF: Change at Week 22 (n= 4, 3, 4) |
|
| CF: Change at Week 26/EOS (n= 2, 2, 3) |
|
| TDS: Baseline (n= 4, 3, 4) |
|
| TDS: Change at Week 22 (n= 4, 3, 4) |
|
| TDS: Change at Week 26/EOS (n= 2, 2, 3) |
|
|
| CC: Change at Week 26/EOS (n= 3, 2, 2) |
|
| PC: Baseline (n= 3, 2, 4) |
|
| PC: Change at Week 22 (n= 1, 0, 1) |
|
| PC: Change at Week 26/EOS (n= 0, 0, 0) |
|
| Orality: Baseline (n= 2, 3, 3) |
|
| Orality: Change at Week 22 (n= 2, 3, 1) |
|
| Orality: Change at Week 26/EOS (n= 1, 1, 1) |
|
| BM: Baseline (n= 4, 4, 2) |
|
| BM: Change at Week 22 (n= 3, 4, 2) |
|
| BM: Change at Week 26/EOS (n= 3, 2, 2) |
|
| IWO: Baseline (n= 4, 3, 4) |
|
| IWO: Change at Week 22 (n= 4, 3, 3) |
|
| IWO: Change at Week 26/EOS (n= 2, 1, 3) |
|
| AAR: Baseline (n= 1, 3, 4) |
|
| AAR: Change at Week 22 (n= 1, 3, 4) |
|
| AAR: Change at Week 26/EOS (n= 0, 1, 3) |
|
| EF: Baseline (n= 3, 4, 4) |
|
| EF: Change at Week 22 (n= 3, 4, 4) |
|
| EF: Change at Week 26/EOS (n= 2, 2, 3) |
|
| SC: Baseline (n= 4, 4, 4) |
|
| SC: Change at Week 22 (n= 4, 4, 4) |
|
| SC: Change at Week 26/EOS (n= 3, 2, 3) |
|
| Fearfulness: Baseline (n= 3, 3, 3) |
|
| Fearfulness: Change at Week 22 (n= 3, 3, 3) |
|
| Fearfulness: Change at Week 26/EOS (n= 2, 1, 3) |
|
| SI: Baseline (n= 4, 4, 4) |
|
| SI: Change at Week 22 (n= 4, 3, 4) |
|
| SI: Change at Week 26/EOS (n= 3, 2, 3) |
|
| EC: Baseline (n= 4, 4, 3) |
|
| EC: Change at Week 22 (n= 4, 4, 3) |
|
| EC: Change at Week 26/EOS (n= 3, 2, 3) |
|
| EE: Baseline (n= 2, 4, 4) |
|
| EE: Change at Week 22 (n= 1, 4, 4) |
|
| EE: Change at Week 26/EOS (n= 0, 2, 3) |
|
| CS: Baseline (n= 4, 3, 4) |
|
| CS: Change at Week 22 (n= 3, 3, 3) |
|
| CS: Change at Week 26/EOS (n= 2, 1, 3) |
|
| Attention: Baseline (n= 4, 4, 4) |
|
| Attention: Change at Week 22 (n= 4, 4, 4) |
|
| Attention: Change at Week 26/EOS (n= 2, 2, 3) |
|
| SCC: Baseline (n= 4, 4, 4) |
|
| SCC: Change at Week 22 (n= 3, 4, 4) |
|
| SCC: Change at Week 26/EOS (n= 3, 2, 3) |
|
| MAA: Baseline (n= 4, 3, 4) |
|
| MAA: Change at Week 22 (n= 2, 3, 4) |
|
| MAA: Change at Week 26/EOS (n= 3, 1, 3) |
|
| SG: Baseline (n= 4, 3, 4) |
|
| SG: Change at Week 22 (n= 3, 3, 4) |
|
| SG: Change at Week 26/EOS (n= 3, 1, 3) |
|
|
|
| PF: Change at Week 26/EOS (n= 1, 2, 1) |
|
| RP: Baseline (n= 2, 4, 2) |
|
| RP: Change at Week 22 (n= 2, 4, 2) |
|
| RP: Change at Week 26/EOS (n= 1, 2, 1) |
|
| BP: Baseline (n= 2, 4, 2) |
|
| BP: Change at Week 22 (n= 2, 4, 2) |
|
| BP: Change at Week 26/EOS (n= 1, 2, 1) |
|
| GH: Baseline (n= 2, 4, 2) |
|
| GH: Change at Week 22 (n= 2, 4, 2) |
|
| GH: Change at Week 26/EOS(n= 1, 2, 1) |
|
| REB: Baseline (n= 2, 4, 2) |
|
| REB: Change at Week 22 (n= 2, 4, 2) |
|
| REB: Change at Week 26/EOS (n= 1, 2, 1) |
|
| BE: Baseline (n= 2, 4, 2) |
|
| BE: Change at Week 22 (n= 2, 4, 2) |
|
| BE: Change at Week 26/EOS (n= 1, 2, 1) |
|
| MH: Baseline (n= 2, 4, 2) |
|
| MH: Change at Week 22 (n= 2, 4, 2) |
|
| MH: Change at Week 26/EOS (n= 1, 2, 1) |
|
| SE: Baseline (n= 2, 4, 2) |
|
| SE: Change at Week 22 (n= 2, 4, 2) |
|
| SE: Change at Week 26/EOS (n= 1, 2, 1) |
|
| PE: Baseline (n= 2, 4, 2) |
|
| PE: Change at Week 22 (n= 2, 4, 2) |
|
| PE: Change at Week 26/EOS (n= 1, 2, 1) |
|
| PT: Baseline (n= 2, 4, 2) |
|
| PT: Change at Week 22 (n= 2, 4, 2) |
|
| PT: Change at Week 26/EOS (n= 1, 2, 1) |
|
| FA: Baseline (n= 2, 4, 2) |
|
| FA: Change at Week 22 (n= 2, 4, 2) |
|
| FA: Change at Week 26/EOS (n= 1, 2, 1) |
|
| FC: Baseline (n= 2, 4, 2) |
|
| FC: Change at Week 22 (n= 2, 4, 2) |
|
| FC: Change at Week 26/EOS (n= 1, 2, 1) |
|
| SM Physical: Baseline (n= 2, 4, 2) |
|
| SM Physical: Change at Week 22 (n= 2, 4, 2) |
|
| SM Physical: Change at Week 26/EOS (n= 1, 2, 1) |
|
| SM Psychosocial: Baseline (n= 2, 4, 2) |
|
| SM Psychosocial: Change at Week 22 (n= 2, 4, 2) |
|
| SM Psychosocial:Change at Week 26/EOS (n= 1, 2, 1) |
|
|
| OH: Change at Week 26/EOS (n= 1, 0, 0) |
|
| PA: Baseline (n= 2, 3, 2) |
|
| PA: Change at Week 22 (n= 2, 2, 2) |
|
| PA: Change at Week 26/EOS (n= 1, 0, 0) |
|
| GAD: Baseline (n= 2, 3, 2) |
|
| GAD: Change at Week 22 (n= 2, 2, 2) |
|
| GAD: Change at Week 26/EOS (n= 1, 0, 0) |
|
| BP: Baseline (n= 2, 3, 2) |
|
| BP: Change at Week 22 (n= 2, 2, 2) |
|
| BP: Change at Week 26/EOS (n= 1, 0, 0) |
|
| TAM: Baseline (n= 2, 3, 2) |
|
| TAM: Change at Week 22 (n= 2, 2, 2) |
|
| TAM: Change at Week 26/EOS (n= 1, 0, 0) |
|
| GEB: Baseline (n= 2, 3, 2) |
|
| GEB: Change at Week 22 (n= 2, 2, 2) |
|
| GEB: Change at Week 26/EOS (n= 1, 0, 0) |
|
| GLB: Baseline (n= 2, 3, 2) |
|
| GLB: Change at Week 22 (n= 2, 2, 2) |
|
| GLB: Change at Week 26/EOS (n= 1, 0, 0) |
|
| GA: Baseline (n= 2, 3, 2) |
|
| GA: Change at Week 22 (n= 2, 2, 2) |
|
| GA: Change at Week 26/EOS (n= 1, 0, 0) |
|
| GHP: Baseline (n= 2, 3, 2) |
|
| GHP: Change at Week 22 (n= 2, 2, 2) |
|
| GHP: Change at Week 26/EOS (n= 1, 0, 0) |
|
| PIE: Baseline (n= 2, 3, 2) |
|
| PIE: Change at Week 22 (n= 2, 2, 2) |
|
| PIE: Change at Week 26/EOS (n= 1, 0, 0) |
|
| PIT: Baseline (n= 2, 3, 2) |
|
| PIT: Change at Week 22 (n= 2, 2, 2) |
|
| PIT: Change at Week 26/EOS (n= 1, 0, 0) |
|
| FC: Baseline (n= 2, 3, 2) |
|
| FC: Change at Week 22 (n= 2, 2, 2) |
|
| FC: Change at Week 26/EOS (n= 1, 0, 0) |
|
|
| BR: Change at Week 26/EOS (n= 3, 2, 2) |
|
| SOD: Baseline (n= 4, 4, 4) |
|
| SOD: Change at Week 22 (n= 4, 4, 4) |
|
| SOD: Change at Week 26/EOS (n= 3, 2, 2) |
|
| SD: Baseline (n= 4, 4, 4) |
|
| SD: Change at Week 22 (n= 4, 4, 4) |
|
| SD: Change at Week 26/EOS (n= 3, 2, 2) |
|
| SA: Baseline (n= 4, 4, 4) |
|
| SA: Change at Week 22 (n= 4, 4, 3) |
|
| SA: Change at Week 26/EOS (n= 3, 2, 2) |
|
| NW: Baseline (n= 4, 4, 4) |
|
| NW: Change at Week 22 (n= 4, 4, 4) |
|
| NW: Change at Week 26/EOS (n= 3, 2, 2) |
|
| P: Baseline (n= 2, 4, 4) |
|
| P: Change at Week 22 (n= 2, 4, 4) |
|
| P: Change at Week 26/EOS (n= 1, 2, 2) |
|
| SDB: Baseline (n= 4, 4, 4) |
|
| SDB: Change at Week 22 (n= 4, 4, 3) |
|
| SDB: Change at Week 26/EOS(n= 3, 2, 2) |
|
| DS: Baseline (n= 4, 4, 4) |
|
| DS: Change at Week 22 (n= 4, 4, 4) |
|
| DS: Change at Week 26/EOS (n= 3, 2, 2) |
|
| TSDS: Baseline (n= 2, 4, 4) |
|
| TSDS: Change at Week 22 (n= 2, 4, 2) |
|
| TSDS: Change at Week 26/EOS (n= 1, 2, 2) |
|
|
| SPTHS: Week 10 (n= 4, 4, 3) |
|
| SPTHS: Change at Week 14 (n= 4, 3, 3) |
|
| SPTHS: Change at Week 22 (n= 4, 4, 4) |
|
| SPNREA: Baseline (n= 4, 4, 4) |
|
| SPNREA: Change at Week 6 (n= 4, 2, 2) |
|
| SPNREA: Change at Week 10 (n= 4, 4, 3) |
|
| SPNREA: Change at Week 14 (n= 4, 3, 3) |
|
| SPNREA: Change at Week 22 (n= 4, 4, 4) |
|
|
| WMV: Baseline |
|
| WMV: Change at Week 22 |
|
| ICSFV: Baseline |
|
| ICSFV: Change at Week 22 |
|
| Right Ear: Change at Week 22 (n= 1, 2, 3) |
|
| Left Ear: Baseline (n= 2, 2, 4) |
|
| Left Ear: Change at Week 22 (n= 2, 2, 4) |
|
|
| RE,IPL III-V: Baseline (n= 3, 3, 3) |
|
| RE,IPL III-V: Change at Week 22 (n= 3, 3, 2) |
|
| RE,IPL I-V: Baseline (n= 3, 3, 3) |
|
| RE,IPL I-V: Change at Week 22 (n= 3, 3, 3) |
|
| LE,IPL I-III: Baseline (n= 3, 3, 4) |
|
| LE,IPL I-III: Change at Week 22 (n= 3, 3, 3) |
|
| LE,IPL III-V: Baseline (n= 3, 3, 4) |
|
| LE,IPL III-V: Change at Week 22 (n= 3, 3, 3) |
|
| LE,IPL I-V: Baseline (n= 3, 3, 4) |
|
| LE,IPL I-V: Week 22 (n= 3, 3, 3) |
|
| IAL: Baseline (n= 3, 3, 3) |
|
| IAL: Change at Week 22 (n= 3, 3, 3) |
|
| AL-RE,WI: Baseline (n= 3, 3, 3) |
|
| AL-RE,WI: Change at Week 22 (n= 3, 3, 3) |
|
| AL-RE,WIII: Baseline (n= 3, 3, 2) |
|
| AL-RE,WIII: Change at Week 22 (n= 3, 3, 2) |
|
| AL-RE,WV: Baseline (n= 3, 3, 3) |
|
| AL-RE,WV: Change at Week 22 (n= 3, 3, 3) |
|
| AL-LE,WI: Baseline (n= 3, 3, 4) |
|
| AL-LE,WI: Change at Week 22 (n= 3, 3, 3) |
|
| AL-LE,WIII: Baseline (n= 3, 3, 4) |
|
| AL-LE,WIII: Change at Week 22 (n= 3, 3, 3) |
|
| AL-LE,WV: Baseline (n= 3, 3, 4) |
|
| AL-LE,WV: Change at Week 22 (n= 3, 3, 4) |
|
|
| RE, Wave III: Baseline (n= 2, 3, 3) |
|
| RE, Wave III: Change at Week 22 (n= 2, 3, 2) |
|
| RE, Wave V: Baseline (n= 2, 3, 3) |
|
| RE, Wave V: Change at Week 22 (n= 2, 3, 3) |
|
| LE, Wave I: Baseline (n= 2, 3, 4) |
|
| LE, Wave I: Change at Week 22 (n= 2, 3, 3) |
|
| LE, Wave III: Baseline (n= 2, 3, 4) |
|
| LE, Wave III: Change at Week 22 (n= 2, 3, 3) |
|
| LE, Wave V: Baseline (n= 2, 3, 4) |
|
| LE, Wave V: Change at Week 22 (n= 2, 3, 4) |
|
|
| A-LE, Wave V/I: Baseline (n= 2, 2, 2) |
|
| A-LE, Wave V/I: Change at Week 22 (n= 2, 1, 1) |
|
| LTA-RE, Wave V/I: Baseline (n= 2, 2, 2) |
|
| LTA-RE, Wave V/I: Change at Week 22 (n= 2, 1, 1) |
|
| LTA-LE, Wave V/I: Baseline (n= 2, 2, 2) |
|
| LTA-LE, Wave V/I: Change at Week 22 (n= 2, 1, 1) |
|
| STA-RE, Wave V/I: Baseline (n= 2, 2, 2) |
|
| STA-RE, Wave V/I: Change at Week 22 (n= 2, 1, 1) |
|
| STA-LE, Wave V/I: Baseline (n= 2, 2, 2) |
|
| STA-LE, Wave V/I: Change at Week 22 (n= 2, 1, 1) |
|
|
| LTL-RE, Wave III: Baseline (n= 3, 3, 3) |
|
| LTL-RE, Wave III: Change at Week 22 (n= 3, 3, 2) |
|
| LTL-RE, Wave V: Baseline (n= 3, 3, 3) |
|
| LTL-RE, Wave V: Change at Week 22 (n= 3, 3, 3) |
|
| LTL-LE, Wave I: Baseline (n= 3, 3, 4) |
|
| LTL-LE, Wave I: Change at Week 22 (n= 3, 3, 3) |
|
| LTL-LE, Wave III: Baseline (n= 3, 3, 4) |
|
| LTL-LE, Wave III: Change at Week 22 (n= 3, 3, 3) |
|
| LTL-LE, Wave V: Baseline (n= 3, 3, 4) |
|
| LTL-LE, Wave V: Change at Week 22 (n= 3, 3, 4) |
|
|
| LTA-RE, Wave III: Baseline (n= 2, 3, 3) |
|
| LTA-RE, Wave III: Change at Week 22 (n= 2, 3, 2) |
|
| LTA-RE, Wave V: Baseline (n= 2, 3, 3) |
|
| LTA-RE, Wave V: Change at Week 22 (n= 2, 3, 3) |
|
| LTA-LE, Wave I: Baseline (n= 2, 3, 4) |
|
| LTA-LE, Wave I: Change at Week 22 (n= 2, 3, 3) |
|
| LTA-LE, Wave III: Baseline (n= 2, 3, 4) |
|
| LTA-LE, Wave III: Change at Week 22 (n= 2, 3, 3) |
|
| LTA-LE, Wave V: Baseline (n= 2, 3, 4) |
|
| LTA-LE, Wave V: Change at Week 22 (n= 2, 3, 4) |
|
|
| STL-RE, Wave III: Baseline (n= 3, 3, 3) |
|
| STL-RE, Wave III:Change at Week 22 (n= 3, 3, 2) |
|
| STL-RE, Wave V: Baseline (n= 3, 3, 3) |
|
| STL-RE, Wave V: Change at Week 22 (n= 3, 3, 3) |
|
| STL-LE, Wave I: Baseline (n= 3, 3, 4) |
|
| STL-LE, Wave I: Change at Week 22 (n= 3, 3, 3) |
|
| STL-LE, Wave III: Baseline (n= 3, 3, 4) |
|
| STL-LE, Wave III: Change at Week 22 (n= 3, 3, 3) |
|
| STL-LE, Wave V: Baseline (n= 3, 3, 4) |
|
| STL-LE, Wave V: Change at Week 22 (n= 3, 3, 4) |
|
|
| STA-RE, Wave III: Baseline (n= 2, 3, 3) |
|
| STA-RE, Wave III: Week 22 (n= 2, 3, 2) |
|
| STA-RE, Wave V: Baseline (n= 2, 3, 3) |
|
| STA-RE, Wave V: Week 22 (n= 2, 3, 3) |
|
| STA-LE, Wave I: Baseline (n= 2, 3, 4) |
|
| STA-LE, Wave I: Week 22 (n= 2, 3, 3) |
|
| STA-LE, Wave III: Baseline (n= 2, 3, 4) |
|
| STA-LE, Wave III: Week 22 (n= 2, 3, 3) |
|
| STA-LE, Wave V: Baseline (n= 2, 3, 4) |
|
| STA-LE, Wave V: Week 22 (n= 2, 3, 4) |
|